Loss of the tumor suppressor gene CDKN2A, encoding p16 and p14, is a frequent event
driving melanoma progression. Therefore, therapeutic strategies aimed at CDKN2A loss …

Synthetic lethality (SL) occurs between two genes when the inactivation of either gene alone
has no effect on cell survival but the inactivation of both genes results in cell death. SL …

Ubiquitination is a reversible post-translational modification based on the chemical addition
of ubiquitin to proteins with regulatory effects on various signaling pathways. Ubiquitination …

Ferroptosis-mediated tumor treatment is constrained by the absence of single-component,
activatable multifunctional inducers. Given this, a topological synthesis strategy is employed …

Mapping genetic interactions and essentiality networks in human cell lines has been used to
identify vulnerabilities of cells carrying specific genetic alterations and to associate novel …

In cancer, synthetic lethality refers to the drug-induced inactivation of one gene and the
inhibition of another in cancer cells by a drug, resulting in the death of only cancer cells; …

Synthetic lethality (SL) describes a situation in which the occurrence of one genetic event
maintains cell viability, whereas the co-occurrence of two genetic events lead to cell death …

Drug-metabolizing enzymes (DMEs) have shown increasing importance in anticancer
therapy. It is not only due to their effect on activation or deactivation of anticancer drugs, but …

Synthetic lethality refers to a genetic interaction where the simultaneous perturbation of
gene pairs leads to cell death. Synthetically lethal gene pairs (SL pairs) provide a potential …

Synthetic lethality (SL) is a type of genetic interaction that occurs when defects in two genes
cause cell death, while a defect in a single gene does not. Targeting an SL partner of a gene …